Global Asthma Biologics Supply, Demand and Key Producers, 2026-2032
The global Asthma Biologics market size is expected to reach $ 14696 million by 2032, rising at a market growth of 10.1% CAGR during the forecast period (2026-2032).
Asthma Biologics refers to marketed monoclonal antibody medicines used as add-on maintenance therapy for patients with moderate-to-severe or severe asthma that remains uncontrolled despite optimized inhaled controller treatment. These therapies act on defined immune pathways involved in allergic and type 2 airway inflammation, principally immunoglobulin E, interleukin-5, interleukin-5 receptor alpha, interleukin-4 receptor alpha and thymic stromal lymphopoietin. Commercial products are supplied mainly as subcutaneous injections in vials, prefilled syringes or other ready-to-use presentations, while intravenous infusion remains relevant for selected anti-IL-5 therapy. Treatment selection is guided by clinical phenotype and biomarkers, including allergic sensitization, serum IgE, blood eosinophils, exacerbation history, oral corticosteroid dependence and broader type 2 inflammatory characteristics. The research scope covers approved and commercially available omalizumab, omalizumab alfa, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab and depemokimab products across adult, adolescent and pediatric asthma settings, with analysis organized by molecule, immune target, clinical phenotype and administration route.
Downstream distribution is centered on hospitals, severe-asthma centers, respiratory and allergy specialists, specialty pharmacies, infusion facilities and payer-authorized treatment networks. Value creation depends on identifying appropriate patients, matching biological mechanisms to phenotypes, securing reimbursement, delivering therapy consistently and documenting clinical outcomes. Specialty-care capabilities and biomarker testing therefore influence commercial performance alongside the medicine itself. Profitability is generally stronger where a product combines differentiated efficacy, convenient administration, broad age coverage and multiple approved indications, while mature anti-IgE products face increasing price and contracting pressure from biosimilars and locally manufactured alternatives.
By clinical group, allergic asthma and eosinophilic asthma remain the core biologic treatment settings, while type 2 inflammatory and broad-phenotype severe asthma are enlarging the addressable population. By administration route, subcutaneous injection is the dominant commercial format because it supports regular outpatient treatment and, for selected products and patients, home administration. Intravenous infusion remains a smaller, specialized segment associated primarily with reslizumab. The most important product-development opportunities lie in extended dosing intervals, convenient ready-to-use presentations, pediatric eligibility and therapies capable of retaining efficacy across less narrowly defined biomarker groups.
China is among the fastest-developing access markets, driven by approvals of additional global biologics, domestic omalizumab products and expanding clinical recognition of phenotype-guided severe-asthma treatment. Mabpharm Limited and CSPC Pharmaceutical Group Limited have strengthened the local anti-IgE supply base, while recent approval of an ultra-long-acting anti-IL-5 product has broadened the available mechanism and dosing portfolio. Japan is also extending treatment access through new long-acting and pediatric approvals. Across other emerging markets, growth remains closely linked to reimbursement development, specialist capacity, biomarker availability and cold-chain coverage rather than disease prevalence alone.
This report is a detailed and comprehensive analysis of the world market for Asthma Biologics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Asthma Biologics that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Asthma Biologics market
2. What is the demand of the global Asthma Biologics market?
3. What is the year over year growth of the global Asthma Biologics market?
4. What is the total value of the global Asthma Biologics market?
5. Who are the Major Players in the global Asthma Biologics market?
6. What are the growth factors driving the market demand?
Asthma Biologics refers to marketed monoclonal antibody medicines used as add-on maintenance therapy for patients with moderate-to-severe or severe asthma that remains uncontrolled despite optimized inhaled controller treatment. These therapies act on defined immune pathways involved in allergic and type 2 airway inflammation, principally immunoglobulin E, interleukin-5, interleukin-5 receptor alpha, interleukin-4 receptor alpha and thymic stromal lymphopoietin. Commercial products are supplied mainly as subcutaneous injections in vials, prefilled syringes or other ready-to-use presentations, while intravenous infusion remains relevant for selected anti-IL-5 therapy. Treatment selection is guided by clinical phenotype and biomarkers, including allergic sensitization, serum IgE, blood eosinophils, exacerbation history, oral corticosteroid dependence and broader type 2 inflammatory characteristics. The research scope covers approved and commercially available omalizumab, omalizumab alfa, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab and depemokimab products across adult, adolescent and pediatric asthma settings, with analysis organized by molecule, immune target, clinical phenotype and administration route.
Key Findings
- The average gross profit margin of this product is 84%
- Severe uncontrolled asthma remains the core commercial treatment setting
- Type 2 inflammation underpins most approved biologic treatment pathways
- Subcutaneous administration dominates marketed asthma biologic formulations globally
- Anti IgE therapy is entering an active biosimilar competition phase
- Longer dosing intervals are becoming a major product differentiator
- China is expanding access through approvals and domestic biologic launches
Market Trends
The Asthma Biologics market is moving from basic target expansion toward comprehensive treatment optimization across response depth, dosing burden, patient selection and continuity of care. Earlier products established anti-IgE and eosinophil-directed treatment, while IL-4Rα and upstream TSLP inhibition broadened the range of addressable severe-asthma phenotypes. The latest commercial shift is toward longer dosing intervals, illustrated by the introduction of six-month anti-IL-5 administration, alongside wider adoption of prefilled devices and selected self-administration pathways. Biomarker results and clinical history are also being combined more systematically to improve initial biologic matching and subsequent switching decisions. Product value is increasingly evaluated through exacerbation reduction, oral corticosteroid sparing, lung-function preservation, pediatric applicability, treatment persistence and the potential to support clinical remission. Biosimilar entry in omalizumab is beginning to reshape the mature anti-IgE segment, increasing price competition and access while preserving the need for specialist-led treatment selection and monitoring.Market Dynamics
Drivers
Demand for Asthma Biologics is supported by the persistent population of patients whose disease remains uncontrolled despite optimized inhaled therapies and who continue to experience recurrent exacerbations, hospitalization risk or maintenance oral corticosteroid exposure. Clinical guidance provides an increasingly structured pathway for selecting anti-IgE, anti-IL-5 or anti-IL-5R, anti-IL-4R and anti-TSLP therapies using phenotype, biomarkers, exacerbation history and relevant comorbidities. Broader pediatric approvals, expanding specialist severe-asthma networks and increasing recognition of corticosteroid-related burden are enlarging the addressable treatment population. Commercial adoption is further supported by evidence that appropriately selected biologic therapy can reduce exacerbations and improve disease control. Recent approvals of long-acting products and additional injection presentations have also widened the available treatment choices in major pharmaceutical markets.Restraints
High acquisition costs and variable reimbursement criteria remain the principal restraints on broader biologic penetration. Access frequently depends on prior treatment failure, documented exacerbations, biomarker thresholds and specialist authorization, which can delay initiation even where clinical need is substantial. The market is also constrained by phenotype overlap, incomplete response among some patients and the absence of a universally accepted treatment sequence when several biologics appear clinically suitable. Injection logistics, cold-chain requirements and periodic monitoring add operational costs, while intravenous treatment requires infusion capacity. As biosimilars and locally manufactured anti-IgE products enter selected markets, lower prices may improve access but also intensify formulary-driven switching and place pressure on the commercial returns of established products.Opportunities
Future opportunities are concentrated in treatment convenience, earlier patient identification and broader geographic access. Longer-interval dosing can reduce administration burden and improve persistence, while prefilled and self-administration formats can move suitable patients away from repeated facility-based injections. Upstream targets capable of treating a wider severe-asthma population create opportunities beyond narrowly defined allergic or eosinophilic phenotypes. Additional potential exists in pediatric treatment, oral corticosteroid-dependent asthma, recurrent exacerbations despite standard therapy and integrated management of asthma with related type 2 inflammatory conditions. In emerging markets, locally produced antibodies and biosimilars may reduce affordability barriers, provided that quality consistency, specialist education, biomarker testing and reimbursement pathways develop in parallel.Challenges
The central market challenge is demonstrating durable comparative value in a field containing multiple effective mechanisms but limited direct head-to-head evidence in asthma. Treatment choice is complicated by overlapping biomarkers, changing eosinophil levels, comorbid disease and previous corticosteroid exposure, while inadequate response requires timely reassessment and switching. Manufacturers must generate long-term real-world evidence covering treatment persistence, clinical remission, safety and healthcare-resource utilization to support premium pricing and favorable reimbursement. They must also manage biologics manufacturing complexity, cold-chain reliability, pharmacovigilance and differing regional regulatory requirements. As anti-IgE biosimilars expand and new long-acting products enter, competition will increasingly center on net treatment cost, dosing convenience, clinical breadth and payer-defined outcomes rather than target novelty alone.Industry Chain Analysis
The upstream chain for Asthma Biologics consists of antibody discovery technologies, expression cell lines, culture media, single-use bioprocess equipment, bioreactors, purification resins, filtration materials, analytical reagents, primary packaging components and cold-chain infrastructure. The midstream segment covers target validation, cell-line and process development, clinical research, regulatory registration, drug-substance manufacturing, purification, sterile fill-finish, device assembly, batch release and pharmacovigilance. Manufacturing economics are shaped by biologic yield, purification efficiency, facility utilization, quality-control intensity, formulation stability and production scale. Products with established platforms and multiple indications can distribute development and commercial infrastructure costs across a broader revenue base, while new entrants must initially absorb substantial clinical, regulatory and market-access expenditure.Downstream distribution is centered on hospitals, severe-asthma centers, respiratory and allergy specialists, specialty pharmacies, infusion facilities and payer-authorized treatment networks. Value creation depends on identifying appropriate patients, matching biological mechanisms to phenotypes, securing reimbursement, delivering therapy consistently and documenting clinical outcomes. Specialty-care capabilities and biomarker testing therefore influence commercial performance alongside the medicine itself. Profitability is generally stronger where a product combines differentiated efficacy, convenient administration, broad age coverage and multiple approved indications, while mature anti-IgE products face increasing price and contracting pressure from biosimilars and locally manufactured alternatives.
Segment Insights
By molecule and immune target, omalizumab and omalizumab alfa constitute the most established anti-IgE segment, supported by long clinical use and the emergence of biosimilar and domestic alternatives. The IL-5 pathway represents the broadest product group in the confirmed portfolio, covering mepolizumab, reslizumab, benralizumab and depemokimab, with differentiation based on ligand versus receptor targeting, administration route and dosing frequency. Dupilumab extends treatment through IL-4Rα blockade for type 2 inflammatory asthma, while tezepelumab targets the upstream epithelial cytokine TSLP and supports treatment across a broader severe-asthma phenotype. These mechanisms increasingly compete on clinical fit rather than functioning as direct substitutes for every patient.By clinical group, allergic asthma and eosinophilic asthma remain the core biologic treatment settings, while type 2 inflammatory and broad-phenotype severe asthma are enlarging the addressable population. By administration route, subcutaneous injection is the dominant commercial format because it supports regular outpatient treatment and, for selected products and patients, home administration. Intravenous infusion remains a smaller, specialized segment associated primarily with reslizumab. The most important product-development opportunities lie in extended dosing intervals, convenient ready-to-use presentations, pediatric eligibility and therapies capable of retaining efficacy across less narrowly defined biomarker groups.
Downstream Market Opportunities
The principal downstream opportunity lies in patients with moderate-to-severe or severe asthma who remain inadequately controlled despite optimized inhaled corticosteroid-based therapy. Severe-asthma centers and specialist respiratory or allergy practices are the main adoption channels because treatment requires diagnostic confirmation, phenotype assessment, biomarker testing and follow-up evaluation. Commercial expansion can come from earlier referral of frequently exacerbating patients, improved identification of allergic and eosinophilic phenotypes, reduced long-term dependence on oral corticosteroids and wider pediatric access. Additional value can be created through coordinated management of type 2 inflammatory comorbidities, although asthma control remains the central treatment objective within this market scope. Products that reduce appointment frequency or enable appropriate self-administration are positioned to address adherence and capacity constraints in downstream care.Regional Insights
North America represents the most commercially mature regional market for Asthma Biologics, supported by broad regulatory coverage, established severe-asthma referral networks, specialty-pharmacy infrastructure and access to the full range of major immune targets. The region also remains an important launch market for new formulations, biosimilars and extended-interval products. Europe has a similarly broad treatment portfolio, but market access varies more visibly by national health-technology assessment, reimbursement criteria and specialist prescribing rules. Biosimilar omalizumab is expected to have a more pronounced effect in price-sensitive and tender-oriented European channels.China is among the fastest-developing access markets, driven by approvals of additional global biologics, domestic omalizumab products and expanding clinical recognition of phenotype-guided severe-asthma treatment. Mabpharm Limited and CSPC Pharmaceutical Group Limited have strengthened the local anti-IgE supply base, while recent approval of an ultra-long-acting anti-IL-5 product has broadened the available mechanism and dosing portfolio. Japan is also extending treatment access through new long-acting and pediatric approvals. Across other emerging markets, growth remains closely linked to reimbursement development, specialist capacity, biomarker availability and cold-chain coverage rather than disease prevalence alone.
Report Scope
This report studies the global Asthma Biologics demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Asthma Biologics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Asthma Biologics that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Asthma Biologics total market, 2021-2032, (USD Million)
- Global Asthma Biologics total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Asthma Biologics total market, key domestic companies, and share, (USD Million)
- Global Asthma Biologics revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Asthma Biologics total market by Type, CAGR, 2021-2032, (USD Million)
- Global Asthma Biologics total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Asthma Biologics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Asthma Biologics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Asthma Biologics Market, Segmentation by Type:
- Omalizumab
- Mepolizumab
- Reslizumab
- Benralizumab
- Dupilumab
- Other
Global Asthma Biologics Market, Segmentation by Route of Administration:
- Subcutaneous Injection
- Intravenous Infusion
Global Asthma Biologics Market, Segmentation by Antibodies:
- Anti-IgE Monoclonal Antibodies
- Anti-IL-5 Monoclonal Antibodies
- Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Global Asthma Biologics Market, Segmentation by Application:
- Allergic Asthma Biologics
- Eosinophilic Asthma Biologics
- Other
Companies Profiled:
- Novartis
- Roche
- GSK
- AstraZeneca
- Teva Pharmaceutical
- Sanofi
- Regeneron Pharmaceuticals
- Amgen
- Celltrion
- Mabpharm Limited
- CSPC Pharmaceutical
Key Questions Answered
1. How big is the global Asthma Biologics market?2. What is the demand of the global Asthma Biologics market?
3. What is the year over year growth of the global Asthma Biologics market?
4. What is the total value of the global Asthma Biologics market?
5. Who are the Major Players in the global Asthma Biologics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Asthma Biologics Introduction
1.2 World Asthma Biologics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Asthma Biologics Total Market by Region (by Headquarter Location)
1.3.1 World Asthma Biologics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Asthma Biologics Revenue (2021-2032)
1.3.3 China Based Company Asthma Biologics Revenue (2021-2032)
1.3.4 Europe Based Company Asthma Biologics Revenue (2021-2032)
1.3.5 Japan Based Company Asthma Biologics Revenue (2021-2032)
1.3.6 South Korea Based Company Asthma Biologics Revenue (2021-2032)
1.3.7 ASEAN Based Company Asthma Biologics Revenue (2021-2032)
1.3.8 India Based Company Asthma Biologics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Asthma Biologics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Asthma Biologics Consumption Value (2021-2032)
2.2 World Asthma Biologics Consumption Value by Region
2.2.1 World Asthma Biologics Consumption Value by Region (2021-2026)
2.2.2 World Asthma Biologics Consumption Value Forecast by Region (2027-2032)
2.3 United States Asthma Biologics Consumption Value (2021-2032)
2.4 China Asthma Biologics Consumption Value (2021-2032)
2.5 Europe Asthma Biologics Consumption Value (2021-2032)
2.6 Japan Asthma Biologics Consumption Value (2021-2032)
2.7 South Korea Asthma Biologics Consumption Value (2021-2032)
2.8 ASEAN Asthma Biologics Consumption Value (2021-2032)
2.9 India Asthma Biologics Consumption Value (2021-2032)
3 WORLD ASTHMA BIOLOGICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Asthma Biologics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Asthma Biologics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Asthma Biologics in 2025
3.2.3 Global Concentration Ratios (CR8) for Asthma Biologics in 2025
3.3 Asthma Biologics Company Evaluation Quadrant
3.4 Asthma Biologics Market: Overall Company Footprint Analysis
3.4.1 Asthma Biologics Market: Region Footprint
3.4.2 Asthma Biologics Market: Company Product Type Footprint
3.4.3 Asthma Biologics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Asthma Biologics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Asthma Biologics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Asthma Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Asthma Biologics Consumption Value Comparison
4.2.1 United States VS China: Asthma Biologics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Asthma Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Asthma Biologics Companies and Market Share, 2021-2026
4.3.1 United States Based Asthma Biologics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Asthma Biologics Revenue, (2021-2026)
4.4 China Based Companies Asthma Biologics Revenue and Market Share, 2021-2026
4.4.1 China Based Asthma Biologics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Asthma Biologics Revenue, (2021-2026)
4.5 Rest of World Based Asthma Biologics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Asthma Biologics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Asthma Biologics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Asthma Biologics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Omalizumab
5.2.2 Mepolizumab
5.2.3 Reslizumab
5.2.4 Benralizumab
5.2.5 Dupilumab
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Asthma Biologics Market Size by Type (2021-2026)
5.3.2 World Asthma Biologics Market Size by Type (2027-2032)
5.3.3 World Asthma Biologics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1 World Asthma Biologics Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Route of Administration
6.2.1 Subcutaneous Injection
6.2.2 Intravenous Infusion
6.3 Market Segment by Route of Administration
6.3.1 World Asthma Biologics Market Size by Route of Administration (2021-2026)
6.3.2 World Asthma Biologics Market Size by Route of Administration (2027-2032)
6.3.3 World Asthma Biologics Market Size Market Share by Route of Administration (2027-2032)
7 MARKET ANALYSIS BY ANTIBODIES
7.1 World Asthma Biologics Market Size Overview by Antibodies: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Antibodies
7.2.1 Anti-IgE Monoclonal Antibodies
7.2.2 Anti-IL-5 Monoclonal Antibodies
7.2.3 Anti-IL-5 Receptor Alpha Monoclonal Antibodies
7.3 Market Segment by Antibodies
7.3.1 World Asthma Biologics Market Size by Antibodies (2021-2026)
7.3.2 World Asthma Biologics Market Size by Antibodies (2027-2032)
7.3.3 World Asthma Biologics Market Size Market Share by Antibodies (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Asthma Biologics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Allergic Asthma Biologics
8.2.2 Eosinophilic Asthma Biologics
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Asthma Biologics Market Size by Application (2021-2026)
8.3.2 World Asthma Biologics Market Size by Application (2027-2032)
8.3.3 World Asthma Biologics Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis
9.1.1 Novartis Details
9.1.2 Novartis Major Business
9.1.3 Novartis Asthma Biologics Product and Services
9.1.4 Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis Recent Developments/Updates
9.1.6 Novartis Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Asthma Biologics Product and Services
9.2.4 Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 GSK
9.3.1 GSK Details
9.3.2 GSK Major Business
9.3.3 GSK Asthma Biologics Product and Services
9.3.4 GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 GSK Recent Developments/Updates
9.3.6 GSK Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Asthma Biologics Product and Services
9.4.4 AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Teva Pharmaceutical
9.5.1 Teva Pharmaceutical Details
9.5.2 Teva Pharmaceutical Major Business
9.5.3 Teva Pharmaceutical Asthma Biologics Product and Services
9.5.4 Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Teva Pharmaceutical Recent Developments/Updates
9.5.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
9.6 Sanofi
9.6.1 Sanofi Details
9.6.2 Sanofi Major Business
9.6.3 Sanofi Asthma Biologics Product and Services
9.6.4 Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Sanofi Recent Developments/Updates
9.6.6 Sanofi Competitive Strengths & Weaknesses
9.7 Regeneron Pharmaceuticals
9.7.1 Regeneron Pharmaceuticals Details
9.7.2 Regeneron Pharmaceuticals Major Business
9.7.3 Regeneron Pharmaceuticals Asthma Biologics Product and Services
9.7.4 Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.7.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.8 Amgen
9.8.1 Amgen Details
9.8.2 Amgen Major Business
9.8.3 Amgen Asthma Biologics Product and Services
9.8.4 Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Amgen Recent Developments/Updates
9.8.6 Amgen Competitive Strengths & Weaknesses
9.9 Celltrion
9.9.1 Celltrion Details
9.9.2 Celltrion Major Business
9.9.3 Celltrion Asthma Biologics Product and Services
9.9.4 Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Celltrion Recent Developments/Updates
9.9.6 Celltrion Competitive Strengths & Weaknesses
9.10 Mabpharm Limited
9.10.1 Mabpharm Limited Details
9.10.2 Mabpharm Limited Major Business
9.10.3 Mabpharm Limited Asthma Biologics Product and Services
9.10.4 Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Mabpharm Limited Recent Developments/Updates
9.10.6 Mabpharm Limited Competitive Strengths & Weaknesses
9.11 CSPC Pharmaceutical
9.11.1 CSPC Pharmaceutical Details
9.11.2 CSPC Pharmaceutical Major Business
9.11.3 CSPC Pharmaceutical Asthma Biologics Product and Services
9.11.4 CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 CSPC Pharmaceutical Recent Developments/Updates
9.11.6 CSPC Pharmaceutical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Asthma Biologics Industry Chain
10.2 Asthma Biologics Upstream Analysis
10.3 Asthma Biologics Midstream Analysis
10.4 Asthma Biologics Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Asthma Biologics Introduction
1.2 World Asthma Biologics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Asthma Biologics Total Market by Region (by Headquarter Location)
1.3.1 World Asthma Biologics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Asthma Biologics Revenue (2021-2032)
1.3.3 China Based Company Asthma Biologics Revenue (2021-2032)
1.3.4 Europe Based Company Asthma Biologics Revenue (2021-2032)
1.3.5 Japan Based Company Asthma Biologics Revenue (2021-2032)
1.3.6 South Korea Based Company Asthma Biologics Revenue (2021-2032)
1.3.7 ASEAN Based Company Asthma Biologics Revenue (2021-2032)
1.3.8 India Based Company Asthma Biologics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Asthma Biologics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Asthma Biologics Consumption Value (2021-2032)
2.2 World Asthma Biologics Consumption Value by Region
2.2.1 World Asthma Biologics Consumption Value by Region (2021-2026)
2.2.2 World Asthma Biologics Consumption Value Forecast by Region (2027-2032)
2.3 United States Asthma Biologics Consumption Value (2021-2032)
2.4 China Asthma Biologics Consumption Value (2021-2032)
2.5 Europe Asthma Biologics Consumption Value (2021-2032)
2.6 Japan Asthma Biologics Consumption Value (2021-2032)
2.7 South Korea Asthma Biologics Consumption Value (2021-2032)
2.8 ASEAN Asthma Biologics Consumption Value (2021-2032)
2.9 India Asthma Biologics Consumption Value (2021-2032)
3 WORLD ASTHMA BIOLOGICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Asthma Biologics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Asthma Biologics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Asthma Biologics in 2025
3.2.3 Global Concentration Ratios (CR8) for Asthma Biologics in 2025
3.3 Asthma Biologics Company Evaluation Quadrant
3.4 Asthma Biologics Market: Overall Company Footprint Analysis
3.4.1 Asthma Biologics Market: Region Footprint
3.4.2 Asthma Biologics Market: Company Product Type Footprint
3.4.3 Asthma Biologics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Asthma Biologics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Asthma Biologics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Asthma Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Asthma Biologics Consumption Value Comparison
4.2.1 United States VS China: Asthma Biologics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Asthma Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Asthma Biologics Companies and Market Share, 2021-2026
4.3.1 United States Based Asthma Biologics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Asthma Biologics Revenue, (2021-2026)
4.4 China Based Companies Asthma Biologics Revenue and Market Share, 2021-2026
4.4.1 China Based Asthma Biologics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Asthma Biologics Revenue, (2021-2026)
4.5 Rest of World Based Asthma Biologics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Asthma Biologics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Asthma Biologics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Asthma Biologics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Omalizumab
5.2.2 Mepolizumab
5.2.3 Reslizumab
5.2.4 Benralizumab
5.2.5 Dupilumab
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Asthma Biologics Market Size by Type (2021-2026)
5.3.2 World Asthma Biologics Market Size by Type (2027-2032)
5.3.3 World Asthma Biologics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1 World Asthma Biologics Market Size Overview by Route of Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Route of Administration
6.2.1 Subcutaneous Injection
6.2.2 Intravenous Infusion
6.3 Market Segment by Route of Administration
6.3.1 World Asthma Biologics Market Size by Route of Administration (2021-2026)
6.3.2 World Asthma Biologics Market Size by Route of Administration (2027-2032)
6.3.3 World Asthma Biologics Market Size Market Share by Route of Administration (2027-2032)
7 MARKET ANALYSIS BY ANTIBODIES
7.1 World Asthma Biologics Market Size Overview by Antibodies: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Antibodies
7.2.1 Anti-IgE Monoclonal Antibodies
7.2.2 Anti-IL-5 Monoclonal Antibodies
7.2.3 Anti-IL-5 Receptor Alpha Monoclonal Antibodies
7.3 Market Segment by Antibodies
7.3.1 World Asthma Biologics Market Size by Antibodies (2021-2026)
7.3.2 World Asthma Biologics Market Size by Antibodies (2027-2032)
7.3.3 World Asthma Biologics Market Size Market Share by Antibodies (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Asthma Biologics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Allergic Asthma Biologics
8.2.2 Eosinophilic Asthma Biologics
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Asthma Biologics Market Size by Application (2021-2026)
8.3.2 World Asthma Biologics Market Size by Application (2027-2032)
8.3.3 World Asthma Biologics Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis
9.1.1 Novartis Details
9.1.2 Novartis Major Business
9.1.3 Novartis Asthma Biologics Product and Services
9.1.4 Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis Recent Developments/Updates
9.1.6 Novartis Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Asthma Biologics Product and Services
9.2.4 Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 GSK
9.3.1 GSK Details
9.3.2 GSK Major Business
9.3.3 GSK Asthma Biologics Product and Services
9.3.4 GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 GSK Recent Developments/Updates
9.3.6 GSK Competitive Strengths & Weaknesses
9.4 AstraZeneca
9.4.1 AstraZeneca Details
9.4.2 AstraZeneca Major Business
9.4.3 AstraZeneca Asthma Biologics Product and Services
9.4.4 AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 AstraZeneca Recent Developments/Updates
9.4.6 AstraZeneca Competitive Strengths & Weaknesses
9.5 Teva Pharmaceutical
9.5.1 Teva Pharmaceutical Details
9.5.2 Teva Pharmaceutical Major Business
9.5.3 Teva Pharmaceutical Asthma Biologics Product and Services
9.5.4 Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Teva Pharmaceutical Recent Developments/Updates
9.5.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
9.6 Sanofi
9.6.1 Sanofi Details
9.6.2 Sanofi Major Business
9.6.3 Sanofi Asthma Biologics Product and Services
9.6.4 Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Sanofi Recent Developments/Updates
9.6.6 Sanofi Competitive Strengths & Weaknesses
9.7 Regeneron Pharmaceuticals
9.7.1 Regeneron Pharmaceuticals Details
9.7.2 Regeneron Pharmaceuticals Major Business
9.7.3 Regeneron Pharmaceuticals Asthma Biologics Product and Services
9.7.4 Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.7.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.8 Amgen
9.8.1 Amgen Details
9.8.2 Amgen Major Business
9.8.3 Amgen Asthma Biologics Product and Services
9.8.4 Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Amgen Recent Developments/Updates
9.8.6 Amgen Competitive Strengths & Weaknesses
9.9 Celltrion
9.9.1 Celltrion Details
9.9.2 Celltrion Major Business
9.9.3 Celltrion Asthma Biologics Product and Services
9.9.4 Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Celltrion Recent Developments/Updates
9.9.6 Celltrion Competitive Strengths & Weaknesses
9.10 Mabpharm Limited
9.10.1 Mabpharm Limited Details
9.10.2 Mabpharm Limited Major Business
9.10.3 Mabpharm Limited Asthma Biologics Product and Services
9.10.4 Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Mabpharm Limited Recent Developments/Updates
9.10.6 Mabpharm Limited Competitive Strengths & Weaknesses
9.11 CSPC Pharmaceutical
9.11.1 CSPC Pharmaceutical Details
9.11.2 CSPC Pharmaceutical Major Business
9.11.3 CSPC Pharmaceutical Asthma Biologics Product and Services
9.11.4 CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 CSPC Pharmaceutical Recent Developments/Updates
9.11.6 CSPC Pharmaceutical Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Asthma Biologics Industry Chain
10.2 Asthma Biologics Upstream Analysis
10.3 Asthma Biologics Midstream Analysis
10.4 Asthma Biologics Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Asthma Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Asthma Biologics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Asthma Biologics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Asthma Biologics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Asthma Biologics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Asthma Biologics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Asthma Biologics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Asthma Biologics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Asthma Biologics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Asthma Biologics Players in 2025
Table 12. World Asthma Biologics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Asthma Biologics Company Evaluation Quadrant
Table 14. Head Office of Key Asthma Biologics Players
Table 15. Asthma Biologics Market: Company Product Type Footprint
Table 16. Asthma Biologics Market: Company Product Application Footprint
Table 17. Asthma Biologics Mergers & Acquisitions Activity
Table 18. United States VS China Asthma Biologics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Asthma Biologics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Asthma Biologics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Asthma Biologics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 23. China Based Asthma Biologics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Asthma Biologics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Asthma Biologics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Asthma Biologics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 29. World Asthma Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Asthma Biologics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Asthma Biologics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Asthma Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 33. World Asthma Biologics Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 34. World Asthma Biologics Market Size by Route of Administration (2027-2032) & (USD Million)
Table 35. World Asthma Biologics Market Size by Antibodies, (USD Million), 2021 & 2025 & 2032
Table 36. World Asthma Biologics Market Size Value by Antibodies (2021-2026) & (USD Million)
Table 37. World Asthma Biologics Market Size by Antibodies (2027-2032) & (USD Million)
Table 38. World Asthma Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Asthma Biologics Market Size by Application (2021-2026) & (USD Million)
Table 40. World Asthma Biologics Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis Basic Information, Manufacturing Base and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Asthma Biologics Product and Services
Table 44. Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Asthma Biologics Product and Services
Table 50. Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. GSK Basic Information, Manufacturing Base and Competitors
Table 54. GSK Major Business
Table 55. GSK Asthma Biologics Product and Services
Table 56. GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. GSK Recent Developments/Updates
Table 58. GSK Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Asthma Biologics Product and Services
Table 62. AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. Teva Pharmaceutical Major Business
Table 67. Teva Pharmaceutical Asthma Biologics Product and Services
Table 68. Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Teva Pharmaceutical Recent Developments/Updates
Table 70. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 71. Sanofi Basic Information, Manufacturing Base and Competitors
Table 72. Sanofi Major Business
Table 73. Sanofi Asthma Biologics Product and Services
Table 74. Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Sanofi Recent Developments/Updates
Table 76. Sanofi Competitive Strengths & Weaknesses
Table 77. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 78. Regeneron Pharmaceuticals Major Business
Table 79. Regeneron Pharmaceuticals Asthma Biologics Product and Services
Table 80. Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Regeneron Pharmaceuticals Recent Developments/Updates
Table 82. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 83. Amgen Basic Information, Manufacturing Base and Competitors
Table 84. Amgen Major Business
Table 85. Amgen Asthma Biologics Product and Services
Table 86. Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Amgen Recent Developments/Updates
Table 88. Amgen Competitive Strengths & Weaknesses
Table 89. Celltrion Basic Information, Manufacturing Base and Competitors
Table 90. Celltrion Major Business
Table 91. Celltrion Asthma Biologics Product and Services
Table 92. Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Celltrion Recent Developments/Updates
Table 94. Celltrion Competitive Strengths & Weaknesses
Table 95. Mabpharm Limited Basic Information, Manufacturing Base and Competitors
Table 96. Mabpharm Limited Major Business
Table 97. Mabpharm Limited Asthma Biologics Product and Services
Table 98. Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Mabpharm Limited Recent Developments/Updates
Table 100. Mabpharm Limited Competitive Strengths & Weaknesses
Table 101. CSPC Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 102. CSPC Pharmaceutical Major Business
Table 103. CSPC Pharmaceutical Asthma Biologics Product and Services
Table 104. CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. CSPC Pharmaceutical Recent Developments/Updates
Table 106. CSPC Pharmaceutical Competitive Strengths & Weaknesses
Table 107. Global Key Players of Asthma Biologics Upstream (Raw Materials)
Table 108. Global Asthma Biologics Typical Customers
Table 1. World Asthma Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Asthma Biologics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Asthma Biologics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Asthma Biologics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Asthma Biologics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Asthma Biologics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Asthma Biologics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Asthma Biologics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Asthma Biologics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Asthma Biologics Players in 2025
Table 12. World Asthma Biologics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Asthma Biologics Company Evaluation Quadrant
Table 14. Head Office of Key Asthma Biologics Players
Table 15. Asthma Biologics Market: Company Product Type Footprint
Table 16. Asthma Biologics Market: Company Product Application Footprint
Table 17. Asthma Biologics Mergers & Acquisitions Activity
Table 18. United States VS China Asthma Biologics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Asthma Biologics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Asthma Biologics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Asthma Biologics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 23. China Based Asthma Biologics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Asthma Biologics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Asthma Biologics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Asthma Biologics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Asthma Biologics Revenue Market Share (2021-2026)
Table 29. World Asthma Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Asthma Biologics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Asthma Biologics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Asthma Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 33. World Asthma Biologics Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 34. World Asthma Biologics Market Size by Route of Administration (2027-2032) & (USD Million)
Table 35. World Asthma Biologics Market Size by Antibodies, (USD Million), 2021 & 2025 & 2032
Table 36. World Asthma Biologics Market Size Value by Antibodies (2021-2026) & (USD Million)
Table 37. World Asthma Biologics Market Size by Antibodies (2027-2032) & (USD Million)
Table 38. World Asthma Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Asthma Biologics Market Size by Application (2021-2026) & (USD Million)
Table 40. World Asthma Biologics Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis Basic Information, Manufacturing Base and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Asthma Biologics Product and Services
Table 44. Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Asthma Biologics Product and Services
Table 50. Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. GSK Basic Information, Manufacturing Base and Competitors
Table 54. GSK Major Business
Table 55. GSK Asthma Biologics Product and Services
Table 56. GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. GSK Recent Developments/Updates
Table 58. GSK Competitive Strengths & Weaknesses
Table 59. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 60. AstraZeneca Major Business
Table 61. AstraZeneca Asthma Biologics Product and Services
Table 62. AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. AstraZeneca Recent Developments/Updates
Table 64. AstraZeneca Competitive Strengths & Weaknesses
Table 65. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. Teva Pharmaceutical Major Business
Table 67. Teva Pharmaceutical Asthma Biologics Product and Services
Table 68. Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Teva Pharmaceutical Recent Developments/Updates
Table 70. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 71. Sanofi Basic Information, Manufacturing Base and Competitors
Table 72. Sanofi Major Business
Table 73. Sanofi Asthma Biologics Product and Services
Table 74. Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Sanofi Recent Developments/Updates
Table 76. Sanofi Competitive Strengths & Weaknesses
Table 77. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 78. Regeneron Pharmaceuticals Major Business
Table 79. Regeneron Pharmaceuticals Asthma Biologics Product and Services
Table 80. Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Regeneron Pharmaceuticals Recent Developments/Updates
Table 82. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 83. Amgen Basic Information, Manufacturing Base and Competitors
Table 84. Amgen Major Business
Table 85. Amgen Asthma Biologics Product and Services
Table 86. Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Amgen Recent Developments/Updates
Table 88. Amgen Competitive Strengths & Weaknesses
Table 89. Celltrion Basic Information, Manufacturing Base and Competitors
Table 90. Celltrion Major Business
Table 91. Celltrion Asthma Biologics Product and Services
Table 92. Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Celltrion Recent Developments/Updates
Table 94. Celltrion Competitive Strengths & Weaknesses
Table 95. Mabpharm Limited Basic Information, Manufacturing Base and Competitors
Table 96. Mabpharm Limited Major Business
Table 97. Mabpharm Limited Asthma Biologics Product and Services
Table 98. Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Mabpharm Limited Recent Developments/Updates
Table 100. Mabpharm Limited Competitive Strengths & Weaknesses
Table 101. CSPC Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 102. CSPC Pharmaceutical Major Business
Table 103. CSPC Pharmaceutical Asthma Biologics Product and Services
Table 104. CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. CSPC Pharmaceutical Recent Developments/Updates
Table 106. CSPC Pharmaceutical Competitive Strengths & Weaknesses
Table 107. Global Key Players of Asthma Biologics Upstream (Raw Materials)
Table 108. Global Asthma Biologics Typical Customers
LIST OF FIGURES
Figure 1. Asthma Biologics Picture
Figure 2. World Asthma Biologics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Asthma Biologics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Asthma Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Asthma Biologics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 13. Asthma Biologics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Asthma Biologics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Asthma Biologics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Asthma Biologics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Asthma Biologics Markets in 2025
Figure 27. United States VS China: Asthma Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Asthma Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Asthma Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Asthma Biologics Market Size Market Share by Type in 2025
Figure 31. Omalizumab
Figure 32. Mepolizumab
Figure 33. Reslizumab
Figure 34. Benralizumab
Figure 35. Dupilumab
Figure 36. Other
Figure 37. World Asthma Biologics Market Size Market Share by Type (2021-2032)
Figure 38. World Asthma Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 39. World Asthma Biologics Market Size Market Share by Route of Administration in 2025
Figure 40. Subcutaneous Injection
Figure 41. Intravenous Infusion
Figure 42. World Asthma Biologics Market Size Market Share by Route of Administration (2021-2032)
Figure 43. World Asthma Biologics Market Size by Antibodies, (USD Million), 2021 & 2025 & 2032
Figure 44. World Asthma Biologics Market Size Market Share by Antibodies in 2025
Figure 45. Anti-IgE Monoclonal Antibodies
Figure 46. Anti-IL-5 Monoclonal Antibodies
Figure 47. Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Figure 48. World Asthma Biologics Market Size Market Share by Antibodies (2021-2032)
Figure 49. World Asthma Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World Asthma Biologics Market Size Market Share by Application in 2025
Figure 51. Allergic Asthma Biologics
Figure 52. Eosinophilic Asthma Biologics
Figure 53. Other
Figure 54. World Asthma Biologics Market Size Market Share by Application (2021-2032)
Figure 55. Asthma Biologics Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
Figure 1. Asthma Biologics Picture
Figure 2. World Asthma Biologics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Asthma Biologics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Asthma Biologics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Asthma Biologics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Asthma Biologics Revenue (2021-2032) & (USD Million)
Figure 13. Asthma Biologics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Asthma Biologics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Asthma Biologics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Asthma Biologics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Asthma Biologics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Asthma Biologics Markets in 2025
Figure 27. United States VS China: Asthma Biologics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Asthma Biologics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Asthma Biologics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Asthma Biologics Market Size Market Share by Type in 2025
Figure 31. Omalizumab
Figure 32. Mepolizumab
Figure 33. Reslizumab
Figure 34. Benralizumab
Figure 35. Dupilumab
Figure 36. Other
Figure 37. World Asthma Biologics Market Size Market Share by Type (2021-2032)
Figure 38. World Asthma Biologics Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 39. World Asthma Biologics Market Size Market Share by Route of Administration in 2025
Figure 40. Subcutaneous Injection
Figure 41. Intravenous Infusion
Figure 42. World Asthma Biologics Market Size Market Share by Route of Administration (2021-2032)
Figure 43. World Asthma Biologics Market Size by Antibodies, (USD Million), 2021 & 2025 & 2032
Figure 44. World Asthma Biologics Market Size Market Share by Antibodies in 2025
Figure 45. Anti-IgE Monoclonal Antibodies
Figure 46. Anti-IL-5 Monoclonal Antibodies
Figure 47. Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Figure 48. World Asthma Biologics Market Size Market Share by Antibodies (2021-2032)
Figure 49. World Asthma Biologics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World Asthma Biologics Market Size Market Share by Application in 2025
Figure 51. Allergic Asthma Biologics
Figure 52. Eosinophilic Asthma Biologics
Figure 53. Other
Figure 54. World Asthma Biologics Market Size Market Share by Application (2021-2032)
Figure 55. Asthma Biologics Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
